Company Encyclopedia
View More
name
DaVita
DVA.US
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
380.95 B
DVA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care ServicesIndustry
Industry Ranking26/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-833.79%E
    • Profit Margin5.80%B
    • Gross Margin31.80%C
  • Growth ScoreC
    • Revenue YoY5.14%C
    • Net Profit YoY-6.74%C
    • Total Assets YoY0.30%C
    • Net Assets YoY-39.60%E
  • Cash ScoreB
    • Cash Flow Margin1725.31%B
    • OCF YoY5.14%C
  • Operating ScoreB
    • Turnover0.76B
  • Debt ScoreE
    • Gearing Ratio92.36%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Catalyzing Change in Specialty Care: DaVita Shares Vision for Technology Transformation

    DaVita is addressing the fragmentation in specialty care by leveraging technology to enhance patient engagement and improve care experiences. At the 2024 AHIP Consumer Experience and Digital Health Forum, Joel Haugen emphasized the need for integrated care solutions and collaboration with stakeholders to optimize experiences and reduce inefficiencies. DaVita's mobile app, Care Connect, exemplifies their approach to using technology for better patient and care team engagement.

    Acceswire·
    US
    DVA
    -0.82%
    Acceswire·
    US
    DVA
    -0.82%

    DaVita Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh

    This page provides financial data for DaVita Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh (DVAI34) on TradingView, specifically focusing on tangible book value per share. It displays market status, links to supercharts and various financial overview sections, and details data source attributions for market and reference information.

    TradingView·
    US
    DVA
    -0.82%
    TradingView·
    US
    DVA
    -0.82%

    From Playgrounds to Patient Care: How DaVita Helps Strengthen Communities

    DaVita held its inaugural DaVita Recess in Florida, where over 100 employees built a playground with KaBOOM! for the Boys & Girls Club of Central Florida. This event highlights DaVita's commitment to community health and well-being, emphasizing their philosophy of being a community first, company second. The initiative aims to foster connection, resilience, and opportunity, benefiting both the local community and DaVita's employees.

    Acceswire·
    US
    DVA
    -0.82%
    Acceswire·
    US
    DVA
    -0.82%

    DaVita Inc. Stock Underperforms Wednesday When Compared To Competitors

    DaVita Inc.'s stock fell 1.05% to $120.10 on Wednesday, underperforming compared to competitors like UnitedHealth Group and Icon PLC, which saw gains. The stock is 33.13% below its 52-week high of $179.60. The S&P 500 and Dow Jones both rose during the session.

    Dow Jones·
    US
    DVA
    -0.82%
    Dow Jones·
    US
    DVA
    -0.82%

    DaVita Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

    DaVita Inc. shares rose 1.57% to $121.37 on Tuesday, underperforming compared to competitors like UnitedHealth Group, Icon PLC, and Quest Diagnostics, despite a positive market session. The stock remains 32.42% below its 52-week high of $179.60. The S&P 500 and Dow Jones also saw gains.

    Dow Jones·
    US
    DVA
    -0.82%
    Dow Jones·
    US
    DVA
    -0.82%
    © 2025 Longbridge｜Disclaimer